Knight Therapeutics Signs an Exclusive License Agreement with Onconova for Rigosertib in Canada

 Knight Therapeutics Signs an Exclusive License Agreement with Onconova for Rigosertib in Canada

Knight Therapeutics Signs an Exclusive License Agreement with Onconova for Rigosertib in Canada

Shots:

  • Onconova to receive $25.55M as clinical, regulatory and commercialization milestones and royalties on sales of Rigosertib. Knight therapeutics to receive exclusive rights to commercialize Rigosertib in Canada
  • If approved, Rigosertib would meet the unmet medical need of the patients suffering from myelodysplastic syndromes and is currently being evaluated in P-III INSPIRE study assessing Rigosertib (IV) + BSC vs Physician’s Choice + BSC in patients in a ratio 2:1 with high-risk MDS who had progressed on, failed to respond to, or relapsed on prior treatment with hypomethylating agent
  • Rigosertib is a first-in-class Ras mimetic molecule that blocks the activation of Ras effector protein, currently being developed for with HR-MDS with the potential to be developed for other solid and liquid tumors with Ras pathway activation

Click here to­ read full press release/ article | Ref: Ocnonova  | Image: Ocnonova

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post